No connection

Search Results

EBS vs JNJ

EBS
Emergent BioSolutions Inc.
BEARISH
Price
$8.03
Market Cap
$414.7M
Sector
Healthcare
AI Confidence
85%
JNJ
Johnson & Johnson
NEUTRAL
Price
$237.96
Market Cap
$573.46B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
EBS
8.63
JNJ
21.55
Forward P/E
EBS
2.69
JNJ
18.9
P/B Ratio
EBS
0.8
JNJ
7.03
P/S Ratio
EBS
0.56
JNJ
6.09
EV/EBITDA
EBS
3.8
JNJ
17.81

Profitability

Gross Margin
EBS
49.44%
JNJ
68.08%
Operating Margin
EBS
-15.2%
JNJ
23.97%
Profit Margin
EBS
7.08%
JNJ
28.46%
ROE
EBS
10.46%
JNJ
35.03%
ROA
EBS
5.33%
JNJ
8.68%

Growth

Revenue Growth
EBS
-23.6%
JNJ
9.1%
Earnings Growth
EBS
--
JNJ
48.6%

Financial Health

Debt/Equity
EBS
1.12
JNJ
0.6
Current Ratio
EBS
5.01
JNJ
1.03
Quick Ratio
EBS
2.19
JNJ
0.69

Dividends

Dividend Yield
EBS
--
JNJ
2.19%
Payout Ratio
EBS
0.0%
JNJ
46.6%

AI Verdict

EBS BEARISH

EBS presents as a classic value trap, characterized by a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between its Graham Number ($14.48) and Intrinsic Value ($6.51). While the stock appears cheap on a P/E and P/S basis, this is offset by a severe revenue contraction of -23.6% YoY and negative operating margins (-15.20%). The combination of bearish insider sentiment, a 0/100 technical trend, and extreme earnings volatility suggests that the current price is not yet reflecting the full extent of the fundamental decay.

Strengths
Strong short-term liquidity with a Current Ratio of 5.01
Low valuation multiples (P/E 8.63, P/S 0.56)
Healthy Gross Margin of 49.44%
Risks
Significant revenue decline (-23.6% YoY and -24.04% Q/Q)
Negative operating margins indicating an unsustainable core business model
Bearish insider activity with consistent selling and zero buying
JNJ NEUTRAL

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

Strengths
Exceptional Return on Equity (ROE) of 35.03%
Strong profit margins (28.46%) and gross margins (68.08%)
Consistent earnings beat track record over 25 quarters
Risks
Weak Piotroski F-Score (3/9) indicating declining fundamental health
Bearish insider activity with $58.35M in net sales and zero buys
Low liquidity indicated by a Quick Ratio of 0.69

Compare Another Pair

EBS vs JNJ: Head-to-Head Comparison

This page compares Emergent BioSolutions Inc. (EBS) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile